Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.

International journal of molecular sciences - 10 Nov 2016

Roszkowski Krzysztof, Furtak Jacek, Zurawski Bogdan, Szylberg Tadeusz, Lewandowska Marzena A

Abstract excerpt

The IDH1/2 gene mutations, ATRX loss/mutation, 1p/19q status, and MGMT promoter methylation are increasingly used as prognostic or predictive biomarkers of gliomas. However, the effect of their combination on radiation therapy outcome is discussable. Previously, we demonstrated that the IDH1 c.G395A; p.R132H mutation was associated with longer survival in grade II astrocytoma and GBM (Glioblastoma). Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Methylation
Share to DNA Modification Methylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Treatment Outcome

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27834917
DOI: 10.3390/ijms17111876
PMCID: PMC5133876

Genes

IDH1
MGMT
ATRX

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.PMID 27834917Read ↗

Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.Semantic proximity Read ↗

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma PatientsSemantic proximity Read ↗

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.Semantic proximity Read ↗

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.Semantic proximity Read ↗

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.Semantic proximity Read ↗

Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutationSemantic proximity Read ↗

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.Semantic proximity Read ↗

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?Semantic proximity Read ↗

[IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].Semantic proximity Read ↗

Prognostic Significance of <i>O</i>6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic GliomasSemantic proximity Read ↗

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.Semantic proximity Read ↗

Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.